Lbp Am Sa Increases Stock Holdings in Cencora, Inc. $COR

Lbp Am Sa raised its position in Cencora, Inc. (NYSE:COR) by 67.1% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 104,904 shares of the company’s stock after acquiring an additional 42,137 shares during the period. Lbp Am Sa’s holdings in Cencora were worth $32,786,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in COR. Cornerstone Wealth Group LLC grew its position in Cencora by 1.3% in the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after acquiring an additional 30 shares during the period. Security Financial Services INC. boosted its holdings in Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after purchasing an additional 33 shares during the period. Atlantic Edge Private Wealth Management LLC increased its holdings in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Hemington Wealth Management boosted its stake in shares of Cencora by 12.0% in the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after buying an additional 35 shares during the period. Finally, Quadcap Wealth Management LLC grew its position in shares of Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after buying an additional 36 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the sale, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,316 shares of company stock valued at $7,151,265 in the last ninety days. 0.38% of the stock is currently owned by company insiders.

Cencora Stock Performance

NYSE:COR opened at $353.07 on Monday. The firm has a market cap of $68.49 billion, a price-to-earnings ratio of 44.41, a price-to-earnings-growth ratio of 1.68 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. Cencora, Inc. has a 1-year low of $237.71 and a 1-year high of $377.54. The firm’s fifty day moving average price is $348.49 and its 200 day moving average price is $322.22.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the company posted $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is 30.19%.

Analyst Ratings Changes

Several research analysts have commented on the stock. Robert W. Baird set a $415.00 price target on shares of Cencora in a report on Tuesday, January 13th. Mizuho raised their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company raised their price target on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Jefferies Financial Group raised Cencora from an “underperform” rating to a “buy” rating in a report on Thursday. Finally, Bank of America reduced their price target on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.